Dallas, TX: ReportsandReports announce it will carry Boehringer Ingelheim GmbH: PharmaVitae Profile Market Research Report in its Store.
Browse complete Boehringer Ingelheim GmbH: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Boehringer Ingelheim’s performance against key rivals in the prescription pharmaceutical sector
- Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company’s outlook
- Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant
Table of Content
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Boehringer Ingelheim: PharmaVitae forecasts at a glance 7
Strategic insight 8
Leading position in core markets 8
Focused therapeutic coverage following key successes 8
Specialization can restrict opportunities 9
New launches struggle to match the decline of existing products 10
Drag on growth as historical drivers turn to decline 10
Slowing growth highlights challenges beyond 2013 11
External product deals needed to extend growth 12
Historical reliance upon internal discoveries 12
Tougher competition for late-stage product deals 13
SWOT analysis 14
Strengths 14
Weaknesses 16
Opportunities 16
Threats 18
CHAPTER 3 QUARTERLY NEWS UPDATE 20
Key findings 20
Quarterly sales update, Q408 21
Product developments 23
Deals and alliances 26
Product deals 26
Technology deals 26
M&A activity 27
Company announcements 27
Future product milestones 28
CHAPTER 4 COMPANY INTRODUCTION 29
Key findings 29
Background 30
Current corporate structure 31
Prescription pharmaceuticals 31
Consumer healthcare 31
Industrial customer 32
Animal health 32
M&A history 33
CHAPTER 5 COMPANY SALES 34
Key findings 34
Prescription pharmaceutical sales and growth rate analysis, 2001-13 35
Product analysis 37
Product analysis, 2001-07 37
Product analysis, 2007-13 40
Therapy area analysis 44
Therapy area analysis, 2001-07 45
Therapy area analysis, 2007-13 47
Therapy area focus, 2001-13 50
Geographic analysis 52
Geographic analysis, 2001-07 53
Geographic analysis, 2007-13 54
Geographic focus, 2001-13 56
Launch/core/expiry analysis 58
Explanation of launch/core/expiry analysis 58
Launch analysis, 2007-13 59
Core analysis, 2007-13 62
Expiry analysis, 2007-13 64
Launch/core/expiry configuration, 2007-13 65
Molecule type analysis 68
Molecule type analysis, 2001-07 69
Molecule type analysis, 2007-13 70
Externalization analysis 73
Externalization analysis, 2001-07 74
Externalization analysis, 2007-13 76
CHAPTER 6 COMPANY FINANCIALS 80
Key findings 80
Reconciliation between PharmaVitae-formatted prescription pharma sales and company reported total sales, 2001-07 81
Financial statements, 2001-07 82
Profit and loss account, 2001-07 82
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 84
Key findings 84
Overview 85
Respiratory 86
Spiriva franchise 86
Overview 86
Sales forecast 87
Success driven by unique market position 87
Cardiovascular 89
Micardis franchise 89
Overview 89
Sales forecast 90
Uptake driven by best in class attributes 90
Growth maintained despite competition across 2007-13 91
Pradaxa 92
Overview 92
Sales forecast 93
Uptake driven by unmet need 93
Pradaxa may be adversely affected by DTI history 94
Competition will prevent a greater capture of market share 95
Urology & gender specific health 96
Flomax 96
Overview 96
Sales forecast 97
Market leading BPH treatment 97
Generic erosion dependent upon acheivment of pediatric exclusivity 98
Central nervous system 99
Sifrol/ Mirapex 99
Overview 99
Sales forecast 100
Historically positioned as a market leading treatment for Parkinson’s disease 100
Late entry to once-daily market limits sales potential 101
CHAPTER 8 APPENDIX 103
R&D pipeline 103
References 111
Abbreviations 111
Exchange rates 112
Browse complete Boehringer Ingelheim GmbH: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Boehringer Ingelheim GmbH Market Share Analysis
Boehringer Ingelheim GmbH-Company Report
Boehringer Ingelheim GmbH – SWOT Analysis
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
